ACIU
AC Immune S.A.
NASDAQ · Healthcare · Biotechnology · CH
$2.86
−2.39%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.22
- Revenue estimate
- $247.3K
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- $0.03
- EPS estimate
- -$0.10
- Revenue actual
- $9.8M
- Revenue estimate
- $9.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 10
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +39.4%
- Revenue beats (12Q)
- 7
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026